Dubai Telegraph - Study shows how fast kilos return after ending weight-loss drugs

EUR -
AED 4.240369
AFN 72.15222
ALL 96.010337
AMD 436.919504
ANG 2.066474
AOA 1058.793523
ARS 1611.346204
AUD 1.619451
AWG 2.081217
AZN 1.956813
BAM 1.954992
BBD 2.322141
BDT 141.961354
BGN 1.902418
BHD 0.435943
BIF 3443.207399
BMD 1.154628
BND 1.475803
BOB 8.002694
BRL 5.953725
BSD 1.159021
BTN 106.671933
BWP 15.538581
BYN 3.421487
BYR 22630.709035
BZD 2.32374
CAD 1.569088
CDF 2514.779555
CHF 0.902925
CLF 0.02624
CLP 1036.117313
CNY 7.927964
CNH 7.941814
COP 4277.400294
CRC 546.088594
CUC 1.154628
CUP 30.597642
CVE 110.219467
CZK 24.401878
DJF 206.38474
DKK 7.472313
DOP 70.322776
DZD 152.019482
EGP 60.501383
ERN 17.31942
ETB 179.476842
FJD 2.542721
FKP 0.861459
GBP 0.862986
GEL 3.134839
GGP 0.861459
GHS 12.557812
GIP 0.861459
GMD 84.865656
GNF 10160.978406
GTQ 8.886329
GYD 242.829685
HKD 9.03661
HNL 30.67999
HRK 7.534179
HTG 152.079809
HUF 387.852834
IDR 19508.768085
ILS 3.611873
IMP 0.861459
INR 106.414793
IQD 1518.082222
IRR 1526158.440873
ISK 144.802275
JEP 0.861459
JMD 181.545788
JOD 0.818637
JPY 183.472718
KES 149.235293
KGS 100.972297
KHR 4652.158731
KMF 491.871195
KPW 1039.203539
KRW 1708.901395
KWD 0.354321
KYD 0.96568
KZT 569.203375
LAK 24825.626652
LBP 103846.100171
LKR 360.285917
LRD 212.092383
LSL 18.976577
LTL 3.409316
LVL 0.698422
LYD 7.371955
MAD 10.850618
MDL 19.986743
MGA 4805.015002
MKD 61.626888
MMK 2424.742133
MNT 4122.187229
MOP 9.342467
MRU 46.280084
MUR 53.008821
MVR 17.838953
MWK 2009.669786
MXN 20.47174
MYR 4.534194
MZN 73.792291
NAD 18.976577
NGN 1612.160702
NIO 42.653118
NOK 11.181475
NPR 170.679925
NZD 1.957112
OMR 0.443952
PAB 1.159021
PEN 3.972159
PGK 4.994002
PHP 68.655391
PKR 323.852513
PLN 4.26462
PYG 7511.896763
QAR 4.226054
RON 5.093531
RSD 117.396804
RUB 91.506257
RWF 1693.600357
SAR 4.332422
SBD 9.289193
SCR 16.157733
SDG 693.931492
SEK 10.71179
SGD 1.473265
SHP 0.86627
SLE 28.4012
SLL 24211.971348
SOS 661.229703
SRD 43.267957
STD 23898.468664
STN 24.490201
SVC 10.139538
SYP 128.022081
SZL 18.975161
THB 36.770303
TJS 11.109011
TMT 4.041198
TND 3.396597
TOP 2.780068
TRY 50.935488
TTD 7.863764
TWD 36.731256
TZS 3002.032787
UAH 51.094292
UGX 4282.230969
USD 1.154628
UYU 46.620741
UZS 14079.415542
VES 505.331309
VND 30335.541759
VUV 138.091343
WST 3.13415
XAF 655.68613
XAG 0.013274
XAU 0.000223
XCD 3.12044
XCG 2.088575
XDR 0.815463
XOF 655.68613
XPF 119.331742
YER 275.496587
ZAR 19.12766
ZMK 10393.037421
ZMW 22.542687
ZWL 371.789749
  • RBGPF

    0.1000

    82.5

    +0.12%

  • CMSC

    -0.0100

    23.24

    -0.04%

  • BP

    1.6200

    41.56

    +3.9%

  • BCE

    -0.5000

    25.89

    -1.93%

  • RIO

    0.4000

    92.08

    +0.43%

  • CMSD

    0.0700

    23.15

    +0.3%

  • RELX

    -0.4300

    34.76

    -1.24%

  • RYCEF

    -0.3300

    17.35

    -1.9%

  • BCC

    -0.6400

    71.9

    -0.89%

  • GSK

    -0.1700

    55.15

    -0.31%

  • BTI

    -0.2500

    59.16

    -0.42%

  • NGG

    -0.1600

    89.69

    -0.18%

  • JRI

    0.2100

    12.85

    +1.63%

  • AZN

    -1.6800

    193.31

    -0.87%

  • VOD

    -0.0600

    14.4

    -0.42%

Study shows how fast kilos return after ending weight-loss drugs
Study shows how fast kilos return after ending weight-loss drugs / Photo: Armend NIMANI - AFP/File

Study shows how fast kilos return after ending weight-loss drugs

When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.

Text size:

But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.

A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.

They have been found to help people lose between 15-20 percent of their body weight.

"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.

However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.

This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.

So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.

Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.

While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.

However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.

The researchers projected that the participants would return to their original weight in 18 months.

Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.

People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.

This meant that people taking the drugs regained their weight four times faster.

- 'Starting point, not a cure' -

"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.

But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.

This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.

Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."

"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.

If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.

"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

Y.Rahma--DT